Revolution Medicines, Inc. Warrant Beats Q3 2026 Estimates
Revenue of $28.0M vs. $25.6M expected and adjusted EPS of -$1.90 vs. -$2.35.
Revolution Medicines, Inc. Warrant (RVMDW) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $28.0 million above the $25.6 million estimate, and adjusted EPS was -$1.90, down 18% from a year earlier, above the -$2.35 estimate.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | -$2.35 | -$1.90 | Beat by 19% |
| Revenue | $25.6M | $28.0M | Beat by 9.5% |
By our calculation, revenue was $2.4 million above the estimate and adjusted EPS was $0.45 above it.
Track record
- EPS record. Adjusted EPS beat the estimate in 1 of the last 8 reports, including this one.
What to watch
- Next-quarter estimates. Consensus calls for EPS of -$1.90 and revenue of $184.0 million next quarter, based on 1 analyst.
- Next report. Revolution Medicines, Inc. Warrant is next expected to report on March 1, 2027.
- Estimate record. Whether Revolution Medicines, Inc. Warrant returns to beating EPS estimates, which it did in 1 of its last 8 reports.
- Related coverage. See our reports on Pan American Silver, Liberty Latin America, Comstock Resources and Dave.
Sources: Results are from Revolution Medicines, Inc. Warrant's Nov. 4, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Revolution Medicines, Inc. Warrant's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Pan American Silver Q3 2026 EPS Tops Estimates at $0.69, but Revenue Misses at $987.7M
EarningsLiberty Latin America Falls Short of Q3 2026 Estimates as Revenue Rises 0.4% to $1.12B
EarningsComstock Resources Misses Q3 2026 Estimates as Revenue Falls 15% to $384.4M
EarningsDave Q3 2026 Revenue Tops Estimates at $197.7M, but EPS Misses at $3.30
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.